Moderna's vaccine results boosted its share offering -- and it's hardly a coincidence

[Zorro]

The announcement Monday by Moderna Inc. of preliminary — very preliminary — results from its trial of a possible COVID-19 vaccine seemed at the time to reflect a global thirst for any potentially positive news in the fight against the pandemic.

On Tuesday, it looks rather different. That’s because on the heels of the vaccine announcement, the Cambridge, Mass., biotech firm announced the sale of 17.6 million new shares at a price of $76 each.

That would have been a premium of nearly 14% over the $66.69 price of Moderna stock on Friday. But it’s a 5% discount to the stock’s price at Monday’s closing.

At this valuation, in other words, the shares might have looked overpriced as of Friday. On Tuesday, following a huge burst of positive publicity, they almost look like a bargain.

https://www.latimes.com/business/story/2020-05-19/moderna-vaccine-share-price-coronavirus-covid-19

[Squinch]

1. Donny Bodybags's "vaccine czar" is the former head of Moderna.

And the reported results were based on 8 test subjects out of an original 45. What happened to the other 37?

Another scam brought to you by Donny Bodybags.

[Rstrstx]

2. Did you catch this part?

Moderna is worth watching, but not only for good reasons. The company may have an “in” with the Trump administration, which just appointed its former board member Moncef Slaoui to head the White House vaccine czardom. Slaoui has reported holding $10 million in Moderna stock options, a potential conflict of interest, though the company says he will divest the options.

[Newest Reality]

3. This Adminstration...

This Administration is all about the "fix" being in. Just a mob of cronies doing what cronies do: corruption.

It's just quid pro quo all the way down.

[crickets]

4. It's not about the vaccine -- follow the money. nt